Celldex Therapeutics
CLDX
135 hedge funds and large institutions have $223M invested in Celldex Therapeutics in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 14 closing their positions.
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
24% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 38
9% more capital invested
Capital invested by funds: $204M → $223M (+$18.6M)
5% more funds holding
Funds holding: 129 → 135 (+6)
0.14% more ownership
Funds ownership: 3.71% → 3.84% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less call options, than puts
Call options by funds: $867K | Put options by funds: $1.1M
Top Buyers
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$15.9M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.35M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.47M |
| 5 |
Millennium Management
New York
|
+$1.15M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.6M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$1.13M |
| 4 |
AG
Artal Group
Luxembourg
|
-$927K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$806K |
CLDX Hedge Fund Activity: Q4 2017 in Review
135 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2017, worth a combined $223M — up 9.1% from $204M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CLDX positions and 14 closed out — a net gain of 7 holders — while 47 added to existing stakes and 38 trimmed.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $15.9M. The largest seller was Fidelity Investments, cutting an estimated $3.78M.
- 135 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2017, up from 129 in Q3 2017.
- Funds reported $223M of Celldex Therapeutics stock for Q4 2017, up 9.1% quarter-over-quarter.
- 21 funds opened new Celldex Therapeutics positions in Q4 2017 and 14 closed out, a net change of +7 holders.
- The largest Celldex Therapeutics buyer in Q4 2017 was Columbia Wanger Asset Management, an estimated $15.9M added.
- The largest Celldex Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $3.78M sold.
Based on aggregated 13F filings for Q4 2017.